Natalizumab to fingolimod: Questions answered, unanswered, and unasked

Affiliations

¹ From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR. olaf.stuve@utsouthwestern.edu.
² From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR.

Editorial

Olaf Stüve et al. Neurology. 2015.

. 2015 Jul 7;85(1):14-5.

doi: 10.1212/WNL.0000000000001722. Epub 2015 May 29.

¹ From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR. olaf.stuve@utsouthwestern.edu.
² From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR.

No abstract available

Comment on

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group. Kappos L, et al. Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29. Neurology. 2015. PMID: 26024899 Free PMC article.